Literature DB >> 30808836

Association Between the Lipid Profile and Renal Dysfunction in the Heart Failure Patients.

Hong Zhang1, Shuang Shi2, Xiu-Juan Zhao3, Jun-Kui Wang2, Zhong-Wei Liu2, Fu-Qiang Liu2, Ling Zhu2, Shun-Ming Zhu2, Yong Zhang2, Shuo Pan4.   

Abstract

BACKGROUND/AIMS: In heart failure patients with high prevalence of chronic renal disease (CKD), hospitalization and mortality, whether the lipid profile was associated with renal dysfunction remained unknown. The present study intended to clarify the association between the lipid profile and renal dysfunction in the heart failure patients.
METHODS: 336 hospitalized heart failure patients with left ventricle ejection fraction (LVEF) ≤45% and New York Heart Association (NYHA) class II-IV were enrolled. The estimated glomerular filtration rate (eGFR) < 90 mL/min·1.73 m2 was defined as renal dysfunction. The demographic, clinical data, blood samples and echocardiography were documented. The Pearson simple linear correlation was performed to evaluate the confounding factors correlated with eGFR. The significantly correlated factors were enrolled in Logistic regression as confounding factors to determine the association between the lipid profile and renal dysfunction in the heart failure patients.
RESULTS: 182 patients (54.2%) had renal dysfunction and 154 patients (45.8%) did not have renal dysfunction. The waist circumference, platelet counts, platelet distribution width (PDW), high density lipoprotein-cholesterol (HDL-C), apolipoprotein A1 (apoA1), albumin and left ventricular ejection fraction (LVEF) are positively correlated with eGFR (all P< 0.05). Meanwhile, the age, mean platelet volume (MPV), neutrophilic granulocyte percentage (NEUT%), urea nitrogen (BUN), creatinine and total bilirubin (TBIL) are negatively correlated with eGFR (all P< 0.05). The total cholesterol (TC), triglyceride, low density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) show no correlation with eGFR. After the adjustment of sex, hypertension, diabetes mellitus, age, waist circumference, platelet counts, MPV, PDW, NEUT%, TBIL, albumin and LVEF, HDL-C is the only lipid factor still significantly associated with renal dysfunction in hospitalized heart failure patients (OR=0.119, P=0.003).
CONCLUSION: Among the lipid profile of TC, triglyceride, LDL-C, HDL-C, apo A1 and apo B, the HDL-C is the only lipid factor significantly associated with renal dysfunction in hospitalized heart failure patients.
© 2019 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  EGFR; HDL-C; Heart failure; Lipid; Renal dysfunction

Mesh:

Substances:

Year:  2019        PMID: 30808836     DOI: 10.1159/000498834

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  6 in total

Review 1.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

2.  High serum uric acid is associated with increased arterial stiffness in hypertension.

Authors:  Li-Na An; Ning Rong; Min Ning; Liu-Liu Feng; Zhen-Han Chen; Wei-Qing Liu; Xiao-Chun Ouyang; Fan-Rong Diao; Zhi-Gang Han; Jiang Hong
Journal:  Aging (Albany NY)       Date:  2020-07-23       Impact factor: 5.682

3.  Discrimination of Chronic Kidney Disease and Diabetic Nephropathy and Analysis of Their Related Influencing Factors.

Authors:  Xiumin Liu; Yinpei Guo; Jing Wu; Nan Yao; Han Wang; Bo Li
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-30       Impact factor: 3.168

4.  Association of Early Renal Dysfunction with Lipid Profile Parameters among Hypertensives in Kazakhstan.

Authors:  Alma Nurtazina; Dana Kozhakhmetova; Daulet Dautov; Nurzhanat Khaidarova; Vijay Kumar Chattu
Journal:  Diagnostics (Basel)       Date:  2021-05-12

5.  Increased serum concentration of apolipoprotein B is associated with an increased risk of reaching renal replacement therapy in patients with diabetic kidney disease.

Authors:  Wen-Bo Zhao; Lin Zhu; Tohty Rahman
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

6.  In Vivo Evaluation of the Oral Toxicity of the Chlorobutanol.

Authors:  Dahye Jeong; Hyosook Shin; Jinhee Lee; Junyoung Yang; Kikyung Jung; Jayoung Jeong; Hansol Won; Jaeho Oh
Journal:  Toxics       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.